- Home
- RPD vs AZTA Comparison
RPD vs AZTA Comparison
Compare RPD & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- AZTA
- Stock Information
- Founded
- RPD 2000
- AZTA 1978
- Country
- RPD United States
- AZTA United States
- Employees
- RPD N/A
- AZTA N/A
- Industry
- RPD Computer Software: Prepackaged Software
- AZTA Industrial Machinery/Components
- Sector
- RPD Technology
- AZTA Technology
- Exchange
- RPD Nasdaq
- AZTA Nasdaq
- Market Cap
- RPD 1.5B
- AZTA 1.4B
- IPO Year
- RPD 2015
- AZTA 1995
- Fundamental
- Price
- RPD $22.71
- AZTA $34.43
- Analyst Decision
- RPD Hold
- AZTA Buy
- Analyst Count
- RPD 20
- AZTA 3
- Target Price
- RPD $32.61
- AZTA $45.00
- AVG Volume (30 Days)
- RPD 730.2K
- AZTA 954.7K
- Earning Date
- RPD 08-07-2025
- AZTA 08-05-2025
- Dividend Yield
- RPD N/A
- AZTA N/A
- EPS Growth
- RPD N/A
- AZTA N/A
- EPS
- RPD 0.41
- AZTA N/A
- Revenue
- RPD $849,159,000.00
- AZTA $669,171,000.00
- Revenue This Year
- RPD $2.78
- AZTA N/A
- Revenue Next Year
- RPD $3.91
- AZTA $4.88
- P/E Ratio
- RPD $55.88
- AZTA N/A
- Revenue Growth
- RPD 6.19
- AZTA 8.56
- 52 Week Low
- RPD $21.61
- AZTA $23.91
- 52 Week High
- RPD $44.48
- AZTA $63.58
- Technical
- Relative Strength Index (RSI)
- RPD 44.97
- AZTA 62.82
- Support Level
- RPD $22.30
- AZTA $31.27
- Resistance Level
- RPD $23.26
- AZTA $35.33
- Average True Range (ATR)
- RPD 0.76
- AZTA 1.60
- MACD
- RPD -0.06
- AZTA 0.08
- Stochastic Oscillator
- RPD 14.91
- AZTA 79.87
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.